Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients

What Was Tested

The paper reports a study of Parathyroid Hormone (PTH 1-84) in the context of hyperparathyroidism, published as a randomized controlled trial.

Who Took Part

The age groups tagged for this paper are teenagers, young adults, adults, middle-aged adults, older adults and people over 80, both men and women.

Post hoc analysis of the relationship between PTH and phosphorus levels before and during treatment with cinacalcet in adult subjects on hemodialysis with inadequately controlled SHPT (PTH ≥300 pg/ml) included: (1) correlation of absolute changes from baseline in mean PTH and phosphorus at week 2 and during weeks 13-26; (2) phosphorus levels at baseline and absolute and percent change of phosphorus after cinacalcet administration stratified by baseline PTH level; (3) two regression analyses models were fitted that (a) adjusted for baseline lab values to quantify the relationship between changes in PTH and changes in phosphorus and (b) a multivariate regression analysis that adjusted for clinically relevant subject characteristics.

How the Study Was Run

The design is described as randomized.

Because people in this Parathyroid Hormone (PTH 1-84) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

The subject headings attached to it are Biomarkers, Calcimimetic Agents, Comorbidity, Hyperparathyroidism, Secondary, Hyperphosphatemia, Kidney Failure, Chronic and Parathyroid Hormone.

What This Means in Plain Language

The paper is a randomized study of Parathyroid Hormone (PTH 1-84) in people with hyperparathyroidism.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2012 (Nephron. Clinical practice), a journal based in Switzerland.

More context: the Parathyroid Hormone (PTH 1-84) compound page, Hyperparathyroidism research.